Your search for dabigatran returned 3 results

A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Dabigatran 150mg was superior to warfarin and dabigatran 110mg was noninferior to warfarin for preventing stroke in patients with atrial fibrillation (AF) regardless of CHA2DS2-VASc scores, as shown by the results of a subgroup analysis of the RE-LY trial presented today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Supratherapeutic plasma levels of dabigatran etexilate do not prolong QTc intervals of the electrocardiogram (ECG), as reported from a study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.